FRA:VSC (Germany)
Â
Akt. nach Kapitalherabsetzung
€
0.10
(0%)
Jun 26
Business Description
4SC AG
ISIN : DE000A3E5C40
Share Class Description:
FRA:VSC: Akt. nach KapitalherabsetzungTotal Employee Number:
11Compare
Compare
Traded in other countries / regions
VSC.Germany0R6U.UK IPO Date
2005-12-15Description
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.01 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -1.3 | |||||
Beneish M-Score | -0.08 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 180.5 | |||||
3-Year EBITDA Growth Rate | 5 | |||||
3-Year EPS without NRI Growth Rate | 2.1 | |||||
3-Year Book Growth Rate | -76.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
14-Day RSI | 33.04 | |||||
12-1 Month Momentum % | -83.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.04 | |||||
Quick Ratio | 1.04 | |||||
Cash Ratio | 1.01 | |||||
Days Sales Outstanding | 12.27 | |||||
Days Payable | 2592.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 35.4 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 98.26 | |||||
Operating Margin % | -122.54 | |||||
Net Margin % | -134.4 | |||||
EBITDA Margin % | -112.68 | |||||
ROE % | -905.47 | |||||
ROA % | -41.81 | |||||
ROIC % | -288.71 | |||||
3-Year ROIIC % | -795.53 | |||||
ROC (Joel Greenblatt) % | -41550 | |||||
ROCE % | -459.12 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.11 | |||||
PB Ratio | 5.56 | |||||
Price-to-Tangible-Book | 5 | |||||
EV-to-EBIT | 1.35 | |||||
EV-to-EBITDA | 1.41 | |||||
EV-to-Revenue | -1.59 | |||||
EV-to-Forward-Revenue | 19.74 | |||||
Price-to-GF-Value | 0.03 | |||||
| Price-to-Net-Current-Asset-Value | 5 | |||||
Earnings Yield (Greenblatt) % | 74.07 |
4SC AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
4SC AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 0.2:1 Stock Split | 2021-07-19 | 7.55 (+0.00%) | ||
| 0.2:1 Stock Split | 2015-04-27 | 28.92 (-6.04%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on 4SC AG
No articles.